Evidence map›Paper›PMID 21401576›Full record

ArticleClinical and experimental immunology2011

Epitope specificity of myeloperoxidase antibodies: identification of candidate human immunodominant epitopes.

B F Bruner, E S Vista, D M Wynn, J A James

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Presentation and progression of MPO-ANCA interstitial lung disease.Journal of translational autoimmunity · 2024
    Article
  7. Article
  8. Mechanisms of vascular damage in ANCA vasculitis.Seminars in immunopathology · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

B F BrunerDepartment of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
E S Vista
D M Wynn
J A James
Oklahoma Medical Research Foundation · US

Funding

THE EFFECTS OF ERK PATHWAY INHIBITION ON DNA METHYLATION IN SLEP20RR015577 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CENTOLA, MICHAEL B · 2000 to 2009
$21.5M
VALIDATING NOVEL GENES IMPLICATED IN LEUKOCYTE CHEMOTAXISP20RR020143 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI KAUFMAN, KENNETH M · 2004 to 2011
$21.0M
Program Project in the Genetics of SLEP01AR049084 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2002 to 2012
$12.7M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CHAKRAVARTY, ELIZA F · 2007 to 2017
$6.7M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2009 to 2018
$6.2M
THROMBOCYTOPENIA AND THE GENETICS OF SEVERE LUPUSP50AR048940 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI REICHLIN, MORRIS · 2002 to 2006
$5.8M
Science in a Culture of MentoringP30GM103510 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2012 to 2016
$3.9M
Science in a Culture of MentoringP30RR031152 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2010 to 2011
$2.4M
Fine specificity of scleroderma autoantibodiesR01AR048045 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2001 to 2005
$1.6M
ROLE OF ANTIPROTEINASE 3 IN WEGENER'S VASCULOPATHYR01AI047575 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 1999 to 2003
$1.2M
GENETIC ANALYSIS OF EPITOPE SPREADINGR01AR045451 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 1999 to 2004
$602k
GENETIC ANALYSIS OF EPITOPE SPREADINGR29AR045451 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 1998 to 1998
–
NCRR NIH HHS P20 RR015577NCRR NIH HHS P20 RR020143NCRR NIH HHS P30 RR031152NCRR NIH HHS RR020143NCRR NIH HHS RR15577NIAID NIH HHS AI082714NIAID NIH HHS AI47575NIAID NIH HHS R01 AI047575NIAID NIH HHS U19 AI082714NIAMS NIH HHS AR053483NIAMS NIH HHS AR45451NIAMS NIH HHS AR48045NIAMS NIH HHS AR48940NIAMS NIH HHS AR49084NIAMS NIH HHS P01 AR049084NIAMS NIH HHS P30 AR053483NIAMS NIH HHS P50 AR048940NIAMS NIH HHS R01 AR045451NIAMS NIH HHS R01 AR048045NIGMS NIH HHS P30 GM103510
6 · The paper itself

Abstract

Anti-neutrophil cytoplasmic autoantibodies (ANCA) are a common feature of systemic vasculitides and have been classified as autoimmune conditions based, in part, on these autoantibodies. ANCA are subdivided further based on their primary target: cytoplasm (c-ANCA) or perinuclear region (p-ANCA). p-ANCAs commonly target myeloperoxidase (MPO), an enzyme with microbicidal and degradative activity. MPO antibodies are non-specific for any single disease and found in a variety of vasculitides, most commonly microscopic polyangiitis. Despite their prevalence, their role in human disease pathogenesis remains undefined. We sought to characterize the sequential antigenic determinants of MPO in vasculitis patients with p-ANCA. Of 68 patients with significant levels of p-ANCA, 12 have significant levels of MPO antibodies and were selected for fine specificity epitope mapping. Sequential antigenic targets, including those containing amino acids (aa) 213-222 (WTPGVKRNGF) and aa 511-522 (RLDNRYQPMEPN), were commonly targeted with a prevalence ranging from 33% to 58%. Subsequent analysis of autoantibody binding to the RLDNRYQPMEPN peptide was assessed using a confirmatory enzyme-linked immunosorbent assay format, with six patients displaying significant binding using this method. Antibodies against this epitope, along with four others (aa 393-402, aa 437-446, aa 479-488 and aa 717-726), were reactive to the heavy chain structure of the MPO protein. One epitope, GSASPMELLS (aa 91-100), was within the pro-peptide structure of MPO. B cell epitope prediction algorithms identified all or part of the seven epitopes defined. These results provide major common human anti-MPO immunodominant antigenic targets which can be used to examine further the potential pathogenic mechanisms for these autoantibodies.

Indexed as

AgedAlgorithmsAntibody AffinityAutoantibodiesEpitope MappingEpitopesFemaleHumansImmunodominant EpitopesMaleMiddle AgedPeptide FragmentsPeroxidaseProtein BindingVasculitisAutoantibodiesEpitopesImmunodominant EpitopesPeptide FragmentsPeroxidase

Identifiers

PMID21401576
PMCPMC3087928
OpenAlexW1566291539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.